Decision Resources, Inc., announces the publication of Emerging Markets for Anti-Infectives, a new study that provides strategic analysis for companies marketing current anti- infective drugs and/or planning to launch new products in Argentina, Brazil, and Mexico. These nations have some of the strongest economies and largest populations in Latin America. As such, they represent burgeoning areas for investment by the pharmaceutical industry. Similar in their health care systems, these countries' governments are undertaking bold initiatives to reform their health care delivery capacity and strengthen their pharmaceutical industries.
This report analyzes the capacity of the health care systems of Argentina, Brazil, and Mexico in managing patients who suffer from bacterial lower respiratory tract infections (LRTIs) and hepatitis C virus (HCV) infections over a ten-year (2000-2010) study period. We chose these two diseases for specific reasons:
-- Bacterial LRTIs currently impose a heavy burden on the health of the populations in emerging markets in general and are a considerable source of antibiotic sales in Argentina, Brazil, and Mexico in particular. Therapies in development for the treatment of LRTIs are broader-spectrum agents that offer activity against drug-resistant pathogens with a convenient dosing schedule. These therapies will also offer improved side-effect profiles relative to the currently marketed agents. The most promising therapies in development for LRTIs are Aventis's telithromycin and Abbott's ABT-778 (both ketolides) and GlaxoSmithKline's gemifloxacin (a fluoroquinolone). These drugs are expected to become available in the emerging markets by 2002, 2004, and 2003, respectively. -- The effects of HCV infection on the population-as measured in terms of its associated morbidity and mortality-is only now being realized in these nations. Of the therapies in development for the treatment of HCV infections, the most promising are Schering-Plough's pegylated IFN- alpha-2b and Roche's pegylated IFN-alpha-2a; these agents are expected to be launched in the emerging markets in 2001 and 2002, respectively. The pegylated IFNs offer more attractive, once-weekly dosing schedules.
Emerging Markets for Anti-Infectives offers invaluable market intelligence for pharmaceutical companies competing in this arena. This study is part of the Infectious Disease portfolio, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.
Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or firstname.lastname@example.org. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, 781-296-2553,